GLP-1 Cardiovascular Benefits: Heart Attack, Stroke and Heart Risk

Research brief

How GLP-1 cardiovascular evidence has evolved

What counts as a cardiovascular benefit?

Cardiovascular outcomes trials usually evaluate defined clinical endpoints rather than a vague concept of “heart health.” A common endpoint is major adverse cardiovascular events, or MACE, often defined as cardiovascular death, nonfatal myocardial infarction and nonfatal stroke. Other studies may examine heart-failure hospitalization, urgent heart-failure visits, coronary revascularization, all-cause mortality or composite kidney-cardiovascular outcomes.

This matters because two trials can both be described as showing a “cardiovascular benefit” while measuring different outcomes in different populations. GLP1Scientist therefore separates the outcome, population and drug before interpreting the result.

Cardiovascular evidence timeline

SELECT changed the cardiovascular conversation

The SELECT trial enrolled 17,604 adults with preexisting cardiovascular disease and a BMI of at least 27 who did not have diabetes. Participants were assigned to once-weekly semaglutide 2.4 mg or placebo in addition to usual care. The primary endpoint was cardiovascular death, nonfatal myocardial infarction or nonfatal stroke.

The primary endpoint occurred in 6.5% of participants receiving semaglutide and 8.0% receiving placebo, corresponding to a hazard ratio of 0.80. That translates to a 20% relative reduction in the primary composite endpoint. New England Journal of Medicine: SELECT.

The most important boundary is that SELECT was a secondary-prevention population. Participants already had cardiovascular disease. The trial does not establish the same cardiovascular benefit for otherwise healthy people with overweight or obesity who have no established cardiovascular disease.

Population segmentation: who was actually studied?

FDA cardiovascular indication for Wegovy

In March 2024, the U.S. FDA approved a new indication for Wegovy to reduce the risk of cardiovascular death, heart attack and stroke in adults with cardiovascular disease and either obesity or overweight. The agency also states that Wegovy should be used with a reduced-calorie diet and increased physical activity. FDA cardiovascular indication announcement.

This indication is a drug- and population-specific regulatory action. It should not be rewritten as “all GLP-1 drugs prevent heart attacks” or “Wegovy prevents heart disease in everyone with obesity.” The narrower wording is more accurate and more useful.

What the 2026 ADA Standards say

The 2026 ADA Standards recommend an SGLT2 inhibitor or GLP-1 receptor agonist with demonstrated cardiovascular benefit as part of comprehensive cardiovascular risk reduction and/or glucose-lowering treatment for people with type 2 diabetes who have established ASCVD or CKD. They also recommend GLP-1 receptor agonists with demonstrated cardiovascular benefit for people with type 2 diabetes and established ASCVD, multiple ASCVD risk factors or CKD.

The ADA further notes that cardiovascular benefit is not contingent on A1C lowering. In other words, the cardiovascular role of these medicines is not simply a by-product of glucose lowering. ADA Standards of Care 2026: Cardiovascular Disease and Risk Management.

GLP-1 receptor agonists versus SGLT2 inhibitors

For people with type 2 diabetes and cardiovascular or kidney disease, guidelines often discuss GLP-1 receptor agonists and SGLT2 inhibitors together because both classes have demonstrated cardiovascular benefit, but their strongest evidence domains are not identical. SGLT2 inhibitors have particularly strong roles in heart failure and CKD, while GLP-1 receptor agonists with demonstrated cardiovascular benefit are important in atherosclerotic cardiovascular risk reduction.

The choice is therefore not simply “which class is better.” The answer depends on ASCVD, heart failure, kidney disease, glycemic needs, obesity, tolerability and other patient-specific factors. In selected patients, guidelines allow combined use because the cardiovascular and kidney benefits may be complementary.

Primary prevention and secondary prevention should not be mixed

Secondary prevention means reducing future events in people who already have established cardiovascular disease. SELECT is a secondary-prevention trial because participants had preexisting CVD. Primary prevention asks whether treatment reduces first cardiovascular events in people without established disease.

This distinction is essential for search interpretation. Queries such as “Can semaglutide prevent a heart attack?” sound broad, but the highest-quality evidence may apply only to a defined population. A good evidence page should answer the user's question while preserving that boundary.

Heart attack and stroke: what SELECT can and cannot tell us

SELECT's primary endpoint combined cardiovascular death, nonfatal myocardial infarction and nonfatal stroke. The trial was powered around that composite endpoint. Because confirmatory secondary endpoints were subject to hierarchical testing, isolated component results should not be promoted as though every individual component independently met the same superiority threshold.

The correct top-line conclusion is that semaglutide 2.4 mg reduced the risk of the primary three-component MACE outcome in the studied population. It is more precise than making separate absolute claims for heart attack, stroke or cardiovascular death unless those analyses are described with their statistical context.

What cardiovascular benefit does not replace

GLP-1 therapy does not replace the rest of cardiovascular prevention. Evidence-based management can include lipid lowering, blood-pressure control, smoking cessation, physical activity, dietary intervention, antiplatelet treatment when indicated, diabetes management and disease-specific therapies. The 2026 CKM framework reinforces this multi-risk-factor approach.

That broader context is important because a medication can provide incremental cardiovascular benefit without becoming the sole treatment for cardiovascular risk.

Cardiovascular evidence and kidney disease overlap

Cardiovascular and kidney outcomes are closely connected in diabetes and CKD. The 2026 ADA Standards recommend GLP-1 receptor agonists with demonstrated cardiovascular benefit for people with type 2 diabetes and CKD, while the kidney evidence for semaglutide has also expanded through FLOW. This overlap is one reason GLP1Scientist maintains separate cardiovascular and kidney hubs while linking them through the CKM section.

Read the CKM syndrome overview for the combined cardiovascular, kidney and metabolic framework.

Evidence boundaries to preserve

• Not every GLP-1 drug has identical cardiovascular evidence.
• SELECT studied established CVD plus overweight or obesity without diabetes.
• SELECT should not be generalized to primary prevention.
• Trial evidence and FDA-approved indications are different evidence layers.
• Composite MACE results should not be rewritten as independent proof for every component endpoint.
• Cardiovascular risk reduction remains multimodal.

Key cardiovascular sources

• SELECT: Semaglutide and Cardiovascular Outcomes in Obesity without Diabetes
• FDA: Wegovy cardiovascular risk-reduction indication
• ADA Standards of Care 2026: Cardiovascular Disease and Risk Management
• GLP1Scientist: Cardiovascular-Kidney-Metabolic Syndrome